| Theme | An up-to-date review of the molecular-targeted therapies for inflammatory bowel disease | |
|---|---|---|
| Title | Anti-TNFα agents in inflammatory bowel disease | |
| Publish Date | 2021/09 | |
| Author | Ami Kawamoto | Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University |
| Author | Toshimitsu Fujii | Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University |
| [ Summary ] | Even as new biologics are being developed, anti-TNFα therapy still plays an important role in the treatment of inflammatory bowel diseases(IBD), with proven efficacy in both ulcerative colitis(UC) and Crohn's disease(CD). Secondary loss of response to these agents has been a problem; however, there is growing evidence on the benefits regarding the concomitant use of immunomodulators to suppress the production of anti-drug antibodies, and regarding the measurement of serum drug levels to alleviate the problem. The true impact of anti-TNFα therapy on the long-term prognosis of IBD remains elusive. However, as it is evident that mucosal healing correlates with improved prognosis and a decrease in surgical risk, it may be suggested that active treatment with a treat-to-target strategy would improve the natural history of IBD. | |